Throughput: 480 tests/hour 580 tests/hour with ISE
Test items on board: 36 items + ISE 3 items
Reaction volume: 120– 300 micro-liter
Patient samples on board: 72 patient samples, 30 STAT samples
Reaction volume: 140– 300 micro-liter
Test items on board: 24 items + ISE 3 items / 36 items + ISE 3 items
Patient samples on board: 30 patient samples
Throughput: 270 tests/hour 450 tests/hour with ISE
R1: 140 ～ 300μl (1μl step）
R2: 20 ～ 260μl (1μl step）
News and Announcements
A cohort of youths with obesity and type 2 diabetes who initiated insulin therapy experienced highly variable HbA1c outcomes, with greater insulin sensitivity and higher adiponectin levels associated with improved glycemic response. Previous evaluation of risk factors for glycemic failure in the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study indicated that higher failure rates were associated with beta-cell dysfunction, higher HbA1c at randomization and African American race. The change in total and high molecular weight adiponectin concentrations over the first six months post-randomization in TODAY was predictive of the responsiveness to oral diabetes therapy.
Scientists at the Baylor College of Medicine (Houston, TX, USA) and their associates analyzed data from 253 youths aged 10 to 17 years with obesity and type 2 diabetes for at least two years participating in TODAY study who were enrolled between July 2004 and February 2009, who had a mean of 3.9 visits since initiation of insulin therapy (64% girls; mean age at randomization, 14 years; mean HbA1c at insulin initiation, 10.1%). Insulin glargine was titrated up to 1 U/kg per day (maximum, 100 U) until fasting glucose levels measured by self-monitoring reached 70 mg/dL to 150 mg/dL. Add-on insulin glargine therapy was considered unsuccessful if titration of therapy did not bring fasting blood glucose to target within one month or if HbA1c was greater than 8% at three months or 7% at six months.
The team reported that within 1‐year post-insulin initiation, 33.2% of participants had a consistent HbA1c decrease of ≥0.5%, 46.2% changed HbA1c <0.5%, and 20.6% had an increase ≥0.5%. At randomization into TODAY and at time of insulin initiation, the three glycemia groups were similar in age, sex, race‐ethnicity, pubertal stage, BMI z‐score, diabetes duration, and insulin secretion indices. Consistent HbA1c improvement was associated with higher insulin sensitivity (1/fasting insulin) at randomization and at time of failure, higher adiponectin at randomization, and was not associated with indices of β‐cell function.Read More: LabMedica
The performance of current microfluidic methods for exosome detection is constrained by boundary conditions, as well as fundamental limits to microscale mass transfer and interfacial exosome binding. Some types of cancer, such as ovarian cancer, tend to remain undetected until they are too advanced for treatment to be effective. Now, an innovative tool may be able to detect cancer easily, quickly, and in minuscule amounts of blood. A device, which is called a "3D-nanopatterned microfluidic chip," could successfully detect cancer markers in the tiniest drop of blood or in a component of the blood called plasma.
Biochemists at the University of Kansas (Lawrence, KS, USA) and their colleagues have shown that a microfluidic chip designed with self-assembled three-dimensional herringbone nanopatterns can detect low levels of tumor-associated exosomes in plasma (10 exosomes μL−1, or approximately 200 vesicles per 20 μL of spiked sample) that would otherwise be undetectable by standard microfluidic systems for biosensing. The nanopatterns promote microscale mass transfer, increase surface area and probe density to enhance the efficiency and speed of exosome binding, and permit drainage of the boundary fluid to reduce near-surface hydrodynamic resistance, thus promoting particle–surface interactions for exosome binding.
The scientists used the device for the detection, in 2 μL plasma samples from 20 ovarian cancer patients and 10 age-matched controls, of exosome subpopulations expressing CD24, epithelial cell adhesion molecule and folate receptor alpha proteins. They suggest exosomal folate receptor alpha as a potential biomarker for early detection and progression monitoring of ovarian cancer. The nanolithography-free nanopatterned device should facilitate the use of liquid biopsies for cancer diagnosis.Read More: Lab Medica
Multiple myeloma is the second-most common type of blood cancer. Multiple myeloma occurs when plasma cells in the bone marrow, the cells that produce antibodies, proliferate out of control and lead to various type of organ failure and death. A major stumbling block, in diagnosing myeloma disease is the fact that each patient is unique and current blood tests are incapable of identifying early disease onset and classifying which patient should receive which treatment. Patients whose routine blood tests reveal some hallmarks of the disease in an early and precancerous stage are followed closely with a "watch and wait" strategy, but every year 1% of them will lose in this "Russian roulette" and develop the full-blown myeloma disease.
A large team of international scientists collaborating with the Weizmann Institute of Science (Rehovot, Israel) applied single cell RNA sequencing to study the heterogeneity of 40 individuals along the multiple myeloma progression spectrum, including 11 healthy controls, demonstrating high inter-individual variability that can be explained by expression of known multiple myeloma drivers and additional putative factors.
The new method sequences the RNA in thousands of individual cells from the patient blood or bone marrow, identifying the specific gene program that is active in each individual cell. In order to understand the myeloma cancer blueprint, the scientists first generated a high-resolution model of normal plasma cells by sequencing tens of thousands of cells from healthy individuals undergoing hip-replacements who served as a control group.Read More: Weizmann Institute of Science
Cirrhosis is an end-stage disease that invariably leads to death and it is the 14th most common cause of death in adults worldwide and results in 1.03 million deaths per year. Chronic infection with hepatitis B virus (HBV) is one of the major causes of cirrhosis and 30% of deaths are attributable to HBV. Anemia is a common comorbidity in cirrhosis that is associated with poor prognosis. Erythrocyte abnormalities were clinically important and frequent findings in patients with chronic disease. Mean corpuscular volume (MCV), a measurement of the average volume of red blood cells (RBCs), has been documented to be associated with an increase in many clinical conditions.
Scientists at the Xi"an Jiaotong University (Xi"an, People’s Republic of China) and their colleagues enrolled 463 patients diagnosed as having HBV-related decompensated cirrhosis in a hospital-based cross-sectional study from May 2013 to July 2016. Patients were classified into three groups according to anemia types, diagnosed based on their mean corpuscular volume level. Anemia was defined according to World Health Organization’s hemoglobin thresholds, which is hemoglobin level of less than 130 g/L in males and less than 120 g/L in females. Among the 463 eligible participants, 304 had normocytic anemia, 123 had macrocytic anemia and 36 had microcytic anemia. The average age of participants was 54.3 ± 7.3 years and 63.5% of them were male. The data showed that patients with macrocytic anemia were older and had higher levels of bilirubin, international normalized ratio (INR) and alkaline phosphatase (ALP) compared to patients with normocytic or microcytic anemia. Model for End Stage Liver Disease (MELD) score was also observed to be higher in the macrocytic group. Conversely, the total cholesterol and albumin were relatively low.
The authors concluded that macrocytic anemia was found to be associated with the severity of liver impairment and might be a predictor for short-term mortality in patients with HBV-related decompensated cirrhosis. The study was published on November 1, 2018, in the journal BMC Gastroenterology.Read More: Xi"an Jiaotong University
Subscribe to our newsletter to receive news, updates, and another stuff by email.